Alcântara L. M.,Ferreira T. C. S.,Gadelha F. R.,Miguel D. C. .2018 .Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis. Internation Journal of Parasitology and Drug Resistance, 8(3) : 430-439.
Bhusal C. K.,Sinha S.,Kaur D.,Sehgal R. .2025 .Unravelling drug resistance in leishmaniasis: genomic adaptations and emerging therapies. Frontiers in Molecular Biosciences, 12 : 1573618.
Bilgic-Temel A.,Murrell D. F.,Uzun S. .2019 .Cutaneous leishmaniasis: A neglected disfiguring disease for women. Internation Journal of Womens Dermatology, 5(3) : 158-165.
Buchelt M.,Valero T.,Kinaciyan T.,Walochnik J.,Egg M.,Szelenyi A.,Langer S.,Handisurya A. .2025 .Off-label treatment with miltefosine for complex, pediatric Old World cutaneous leishmaniasis. JAAD Case Reports, 64 : 26-29.
Cecílio P.,Silva A.,Oliveira F. .2022 .Sand flies: Basic information on the vectors of leishmaniasis and their interactions with Leishmania parasites. Communications Biology, 5(1) : 305.
Levatti C. R.,Boité E. V. C.,Lamounier M. C.,Alvar D.,Cupolillo J.,Costa E.,Rode C. H. N.,Uliana J.,S. R. B. J. .2021 .In vitro susceptibility to miltefosine of Leishmania infantum (syn. L. chagasi) isolates from different geographical areas in Brazil. , 9(6) : 1228.
Ginouvès M.,Simon S.,Nacher M.,Demar M.,Carme B.,Couppié P.,Prévot G. .2017 .In Vitro sensitivity of cutaneous Leishmania promastigote isolates circulating in French Guiana to a set of drugs. Americal Journal of Tropical Medicine and Hygiene, 96(5) : 1143-1150.
Goswami R. P.,Rahman M.,Das S.,Tripathi S. K.,Goswami R. P. .2020 .Combination therapy against indian visceral leishmaniasis with liposomal amphotericin B (FungisomeTM) and short-course miltefosine in comparison to miltefosine monotherapy. Americal Journal of Tropical Medicine and Hygiene, 103(1) : 308-314.
Gupta S.,Nishi S. .2011 .Visceral leishmaniasis: Experimental models for drug discovery. Indian Journal of Medical Research, 133(1) : 27-39.
Jafari R.,Najafzadeh N.,Sedaghat M.,Parvizi P. .2013 .Molecular characterization of sandflies and Leishmania detection in main vector of zoonotic cutaneous leishmaniasis in Abarkouh district of Yazd province. Iran. Asian Pacific Journal of Tropical Medicine, : 792-797.
Khademvatan S.,Gharavi M. J.,Saki J. .2011 .Miltefosine induces metacaspase and PARP genes expression in Leishmania infantum. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 15(5) : 442-448.
Khan S.,Kakakhel S. I.,Khan Amir,Shams U.,Shams H.,Rehman S.,Hamza S. .2024 .Comparison of miltefosine with glucantime for the treatment of cutaneous leishmaniasis. Pakistan Journal of Health Sciences, 5(12) : 45-49.
Kumar A.,Pandey S. C.,Samant M. .2018 .Slow pace of antileishmanial drug development. Parasitology Open, 4(e4) : 1-11.
Madha M.,Haddad S.,Khazem M. .2020 .Evaluation of the effect of Peganum harmala extracts on the in vitro viability of Leishmania tropica promastigotes in comparison to Glucantime. Journal of Parasitic Diseases, 44(4) : 858-863.
Mahmoudvand H.,Kheirandish F.,Mirbadie S. R.,Kayedi M. H.,Ghasemi T.,Bamorovat A. A.,Sharifi M.,I. M. .2017 .The Potential use of methotrexate in the treatment of cutaneous leishmaniasis: In vitro assays against sensitive and meglumine antimoniate-resistant strains of Leishmania tropica. Iranian Journa of Parasitology, 12(3) : 339-347.
Mann S.,Frasca K.,Scherrer S.,Henao-Martínez A. F.,Newman S.,Ramanan P.,Suarez J. A. .2021 .A review of leishmaniasis: current knowledge and future directions. Current Tropical Medicine Report, 8(2) : 121-132.
Masne T.,Kumar D.,Bansode D. .2024 .A review of leishmaniasis: Current knowledge and future directions of heterocyclic molecules. Exploration of Drug Science, 508 : 539.
Srisuton P.,Phumee A.,Sunantaraporn S.,Sor-Suwan R.,S. R.,Pengsakul N.,Siriyasatien T.,P. T. .2019 .Detection of Leishmania and Trypanosoma DNA in Field-Caught sand flies from endemic and non-Endemic areas of leishmaniasis in Southern Thailand. , 10(8) : 238.
Sundar S.,Olliaro P. L. .2007 .Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. Therapeutic and Clinical Risk Management, 3(5) : 733-740.
Torres-Guerrero E.,Quintanilla-Cedillo M. R.,Ruiz-Esmenjaud J.,Arenas R. .2017 .Leishmaniasis: a review. F1000Research, 6 : 750.
Ware J. M.,'Connell O,Brown E. M.,Wetzler L.,Talaat K. R.,Nutman T. B.,Nash T. E. .2021 .Efficacy and tolerability of miltefosine in the treatment of cutaneous leishmaniasis. Clinical Infectious Disseases, 73(7) : e2457-e2562.
World Health Organization. .2023 .Leishmaniasis Fact Sheet. , : .
Zghair K. H. .2017 .In Vitro Assessment of miltefosine activity against promastigotes and axenic amastigotes of Leishmania tropica. Iraqi Journal Science, 22 : 30.